Transposons for cancer gene discovery: Sleeping Beauty and beyond by Collier, Lara S & Largaespada, David A
Genome Biology 2007, 8(Suppl 1):S15
Review
Transposons for cancer gene discovery: Sleeping Beauty and beyond
Lara S Collier and David A Largaespada
The Department of Genetics, Cell Biology and Development, The Cancer Center, The University of Minnesota Twin Cities, 
Church St SE, Minneapolis, Minnesota 55455, USA
Correspondence: Lara S Collier. E-mail: lsc5e@alumni.virginia.edu
Abstract
The use of Sleeping Beauty transposons as somatic mutagens to discover cancer genes in
hematopoietic tumors and sarcomas has been documented. Here, we discuss the future of
Sleeping Beauty for cancer genetic studies and the potential use of additional transposable
elements for somatic mutagenesis.
Published: 31 October 2007
Genome Biology 2007, 8(Suppl 1):S15 (doi:10.1186/gb-2007-8-S1-S15)
The electronic version of this article is the complete one and can be
found online at http://genomebiology.com/2007/8/S1/S15
© 2007 BioMed Central Ltd 
Introduction
Cancer genomes are complex, and there are probably many
yet undiscovered tumor suppressor genes (TSGs) and onco-
genes. The multiple mechanisms by which cancer genes can
suffer mutation, including amplification/deletion, point
mutation, and epigenetic silencing, can complicate cancer
gene discovery. Forward genetic approaches for cancer gene
discovery are attractive because they allow unbiased, whole
genome scans for cancer genes. In mice, treatment with
chemical and radiologic mutagens can mutate cancer genes
and promote tumor formation, but identification of the
affected gene is difficult and is often achieved using a
candidate gene approach. The use of insertional mutagens,
such as the Sleeping Beauty (SB) transposon, is attractive
because the inserted sequence serves as a molecular tag to
facilitate identification of the affected gene. Two reports
have been published, those by Collier, Carlson and co-
workers [1] and Dupuy and colleagues [2], on the ability of
somatically mobilized SB transposons to mutagenize, tag,
and thereby lead to the identification of cancer genes. Both
the scientific rationale for these experiments and the
mechanisms by which SB mutagenizes and identifies cancer
genes were recently reviewed [3-5]. In this discussion, we
focus on what lessons can be learned from these two studies
about how to improve the utility of transposon-based
somatic mutagenesis for cancer gene discovery.
SB was the first nonviral insertional mutagen used for
cancer gene identification. However, retroviruses have been
used as powerful insertional somatic mutagens for cancer
gene discovery in mice, as well as other laboratory animals,
for many years [6-10]. Despite the important discoveries
made, retroviruses have several limitations that the use of
nonviral insertional mutagens, such as SB, are expected to
overcome [5].
Retroviruses require cell infection, reverse transcription of
the viral genome, and integration of the resulting provirus
into the host genome to be mutagenic. Murine leukemia
viruses (MuLVs) are frequently used as mutagens in mouse
models of leukemia development. MuLVs and other mouse
retroviruses are unable to infect nondividing cells and do so
very inefficiently in poorly replicating cells [11]. This limits
their utility for insertional mutagenesis in some tissues.
Other tissues have physical barriers, such as the basement
membrane or mucin layer, that prevent efficient infection
with retroviruses [12]. In addition, MuLVs have profound
insertion site bias, and therefore they do not mutagenize the
entire genome equally because they have a strong preference
for landing near the promoter region of actively transcribed
genes [13,14]. Elements such as SB that do not exhibit such a
strong insertion site preference [15] are likely to mutagenize
the genome more completely. Indeed, lymphocytic leukemia
associated genes uncovered using SB include many genes
not previously identified by retroviruses, despite many years
of this kind of work with MuLV [2]. Finally, retroviruses
used in insertional mutagenesis screens must be capable of
efficient infection and spread in the host animal, whichimposes tremendous limitations on the ways in which the
retroviral cargo can be manipulated for specific mutagenesis
projects. SB, and other cut-and-paste transposons, require
only an inverted terminal repeat sequence for transposition
and can therefore be engineered with diverse cargoes of
mutagenic elements.
Lessons from Sleeping Beauty: transposon and
transposase transgene design
The SB system consists of two parts: the transposon and the
enzyme that mobilizes it, the transposase. The SB trans-
poson used for somatic mutagenesis (T2/onc) contains
splice acceptors in both orientations followed by poly-
adenylation signals, so that it can generate loss-of-function
mutations in TSGs. T2/onc also contains sequences from the
murine stem cell virus (MSCV) long terminal repeat (LTR)
that contain enhancer/promoter elements, so that T2/onc
can promote over-expression of proto-oncogenes that are
near to where it lands. The version of T2/onc used by Dupuy
and coworkers [2] contains a longer version of one splice
acceptor, and it is therefore named T2/onc2 to denote this
difference. Although T2/onc and T2/onc2 are similar, the
transgenic lines generated from them harbor dramatically
different numbers of transposon copies residing in a
chromosomal concatomer. T2/onc lines contain approxi-
mately 25 copies of T2/onc [1], whereas the transgenic lines
generated for T2/onc2 contain approximately 150 to 350
copies of transposons in their chromosomal concatomers
[2]. To indicate this difference, we refer to T2/onc lines as
‘low-copy lines’ and T2/onc2 lines as ‘high-copy lines’.
Because tumor formation is hypothesized to require multiple
hits in cancer genes in the same cell [16], it was hypothesized
that having more transposons to mobilize would allow these
hits to occur more rapidly.
Two different transposase transgenic lines have been used in
somatic mutagenesis studies. Collier, Carlson and coworkers
[1] used transgenic mice that express the SB10 version of the
transposase under the control of the theoretically ubiquitous
CAGGS promoter (CAGGS-SB10) [17]. CAGGS-SB10 mice
were generated using standard pronuclear injection
techniques for generating transgenic mice [18]. Dupuy and
colleagues [2] generated mice (R26-SB11) in which the SB11
version of the transposase was knocked into the endogenous
Rosa26 locus using homologous recombination in
embryonic stem cells. Similar targeting of transgenes to the
Rosa26 locus in mice has resulted in essentially ubiquitous
expression during development and in adulthood [19,20].
Although mobilizing T2/onc from low-copy lines by CAGGS-
SB10 could accelerate sarcoma formation in Arf-/- mice, it
was not sufficient to result in tumor formation on an
otherwise wild-type background [1]. Mobilizing T2/onc2
from high-copy lines by R26-SB11 resulted in high levels of
embryonic lethality. Mice that survived to adulthood rapidly
succumbed to tumor formation, primarily lymphocytic
leukemias, by 120 days [2]. The differences in tumor
induction potential between these two studies [1,2] could be
explained by either differences in transposase activity/
expression patterns, transposon copy number, or both.
Recently, a monoclonal antibody directed against the SB
transposase useful for immunohistochemistry has become
commercially available (R&D Systems, Minneapolis, MN,
USA), allowing us to investigate transposase expression in
transgenic mice on a cell-by-cell basis. Although our studies
have not been exhaustive, we observed dramatic differences
in expression between the two transgenics (Figure 1)
(Rahrmann EP, Collier LS, Kuslak SL, Green LE, Largaes-
pada DA, Marker PC, unpublished data) (Collier LS, Lar-
gaespada DA, unpublished data). In general, transposase
expression in CAGGS-SB10 mice is rare, highly variegated,
and mainly mesenchymal in nature (Figure 1b,c) (Rahrmann
EP, Collier LS, Kuslak SL, Green LE, Largaespada DA,
Marker PC, unpublished data). This variegated pattern of
expression probably results from epigenetic silencing, which
is known to occur with traditional transgenes that exist in
multicopy arrays. Transposase is easily detected but
somewhat variegated in the testis of CAGGS-SB10 mice
(Rahrmann EP, Collier LS, Kuslak SL, Green LE, Largaes-
pada DA, Marker PC, unpublished data). Testis expression is
expected because of the ability of CAGGS-SB10 to promote
transposon mobilization efficiently in the male germline
[18,21]. At first glance, these findings appear to contradict
the results of published excision assays, which detected
transposase activity in all tissue types examined in CAGGS-
SB10;T2/onc doubly transgenic mice [1]. However, the
polymerase chain reaction based methods used to detect
excision and therefore transposase activity in CAGGS-
SB10;T2/onc mice are very sensitive and can detect few
mobilization events. In addition, excision assays cannot
accurately address the temporal and spatial pattern of trans-
posase expression in transgenic mice.
In contrast to CAGGS-SB10 transgenics, R26-SB11 trans-
genics express high levels of transposase in virtually every
cell type examined (Figure 1a) (Collier LS, Largaespada DA,
unpublished data). However, extremely high levels of
transposase expression may not always be ideal. In germline
mutagenesis screens, we have generated seed mice for the
same chromosomal concatomer with both R26-SB11 and
CAGGS-SB10. Although the study of offspring generated
from R26-SB11 seed mice was not exhaustive, we found that
mobilization in the germline by CAGGS-SB10 resulted in
more insertions per gamete than did R26-SB11 [21]. One
potential explanation for lower germline transposition rates
using R26-SB11 could be over-expression inhibition. Over-
expression inhibition refers to the observation in cell culture
models that, given a fixed number of SB transposons,
increasing levels of SB transposase eventually lead to a
decrease in transposition efficiency [22]. Although our
observation by no means offers proof that this phenomenon
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high, ubiquitous levels of transposase in R26-SB11 mice - that
tumors or precancerous lesions have only been observed in a
few tissues [2]. Alternatively, although SB mobilization has
been detected in a wide variety of tissue and cell types in vivo
and  in vitro [1,23,24],  in vitro work indicates that cell-
specific factors may play a role in regulating transposition as
transposition rates vary from cell line to cell line [24,25]. We
must await the development of accurate methods to measure
transposition in somatic tissues to examine the relationship
between transposase expression level, transposition
frequencies, and cancer development in vivo. Nevertheless,
improved transposase transgenic lines, or the development of
additional methods to deliver transposase expression
constructs, may be useful for allowing cancer gene discovery
in a wider range of tissue types [26-29].
To address whether transposon copy number influences
tumor formation in somatic mutagenesis studies, we
combined T2/onc low-copy lines with R26-SB11. Unlike what
was reported for high-copy lines, we observed no evidence for
embryonic lethality because the transgenes essentially follow
Mendelian inheritance (Collier LS, Green LE, Davies M,
Dupuy AJ, Copeland NG, Jenkins NA, Largaespada DA,
unpublished data). T2/onc low-copy;R26-SB11 doubly trans-
genic mice live longer than high-copy T2/onc2;R26-SB11
mice, but they also do eventually succumb to primarily
lymphocytic leukemia (Collier LS, Green LE, Diers MD,
Matise I, Largaespada DA, unpublished data). Therefore,
although use of high-copy T2/onc2 lines are attractive
because of the short tumor latency, the Mendelian
inheritance observed with T2/onc low-copy lines and R26-
SB11 allows the generation of larger cohorts of mice, and
therefore more tumors to study, than would be practical with
high-copy lines.
The mutagenic elements carried within a transposon may
also influence its ability to promote tumor formation in
various tissues. Although T2/onc was designed with
elements to cause both loss-of-function and gain-of-function
mutations, insertions that resulted in proto-oncogene over-
expression predominated in both leukemias and sarcomas
[1,2]. It is possible that use of transposons with only loss-of-
function elements will greatly facilitate TSG identification,
especially when coupled with a genetic background in which
mitotic recombination is elevated. The results of an
experimental approach like this were recently reported, in
which retroviral-based mutagenesis was used to accelerate
leukemia formation in Bloom mutant mice [30]. Viral
integrations at certain common insertion sites (CISs) were
shown to have undergone loss-of-heterozygosity, and thus
they are potential new TSGs. However, the vast majority of
viral integrations at all CISs in Bloom mutant leukemias
were located 5’ or 3’ to genes, indicating that the strong
promoter/enhancer activity of the retroviral LTR still
imposes a bias toward proto-oncogene over-expression.
Unlike retroviruses, it is possible to engineer SB vectors that
contain loss-of-function only elements. In terms of oncogene
identification, T2/onc is likely only to be useful in tissues in
which the MSCV LTR is highly active. The use of alternative
promoters in transposons for cancer gene discovery may
allow more robust over-expression of proto-oncogenes in
different cell types [3].
Caveats of cut-and-paste transposons for
mutagenesis: local hops, genome
rearrangements, and remobilization
In tumors initiated or promoted by SB mobilization,
transposons have inserted into or near cancer genes. How-
ever, each tumor contains many transposon integrations,
because approximately 1,000 insertions were cloned from
28 sarcomas whereas 782 insertions were cloned from 16
lymphomas [1,2]. Although some of these insertions in
tumors contribute to tumor formation, some are merely
passenger or bystander insertions that happened to occur in
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Figure 1
Immunohistochemistry staining for SB transposase. Shown is immunohistochemistry staining for Sleeping Beauty (SB) transposase in (a) R26-SB11 mice
and (b,c) CAGGS-SB10 mice. Anti-transposase immunoreactivity is indicated by brown stain and nuclei are counter-stained blue. In panel (a), essentially
all nuclei are positive for transposase in intestine from a R26-SB11 mouse. In panel (b), rare nuclei are positive for transposase in this section of intestine
from a CAGGS-SB10 mouse. In panel (c), variegated mesenchymal transposase expression (asterisk) is detected in muscular tissue from the digestive
tract of a CAGGS-SB10 mouse.a cell that had also suffered insertions in cancer genes. In
order to determine which insertions probably mark the
chromosomal location of a cancer gene, CIS analysis is
performed. CIS analysis looks for clustering of insertions in
tumors above that which is expected by random chance. So-
called Monte Carlo simulations, in which a randomly
generated dataset of theoretical insertions is generated, are
used to determine the amount of clustering that would be
expected simply by random chance [31]. Unlike what is
modeled by a Monte Carlo simulation, SB integration is not
completely random [21,32-35]. On a macro scale, SB has a
slight preference for integrating in and 5’ to RefSeq genes
[15]. A greater caveat with SB mobilized from chromosomal
concatomers is the local hopping phenomenon. Local
hopping refers to the observation that mobilized elements
tend to reinsert near their original location. Local hopping
increases the probability that, at loci linked to the
concatomer, clustering will occur more frequently by random
chance than at other locations in the genome. Therefore,
although clustering of insertions near the concatomer is
often seen, this is not always due to selection for insertions
in or near cancer genes.
In the future, it may be possible to elucidate the influence of
local hopping on CIS identification by performing Monte
Carlo simulations that factor in local hopping rates.
However, this type of analysis would be complicated by the
observation that local hopping rates appear to vary from
concatomer to concatomer and from transposase source to
transposase source [1,2,21,32,34]. An alternative would be to
determine the frequency of ‘background’ CISs linked to the
donor locus by cloning large numbers of control SB
insertions from tissues of transgenic mice that are not under
selection for tumorigenesis. This was done using embryos
from doubly transgenic high-copy T2onc2;R26-SB11 mice
[2]. However, this analysis would have to be performed anew
with every transposon concatomer, transposase combination.
In fact, the rate of SB local hopping in tumors appears to be
much less than that observed in germline mutagenesis
screens. In germline screens, the local hopping rate has been
as high as approximately 58% of insertions occurring within
10 megabases on either side of the donor concatomer [34].
In somatic screens, the local hopping rate calculated from
sarcomas generated using a low-copy donor locus on
chromosome 1 and CAGGS-SB10 was 20% of insertions
found within 20 megabases either side of the concatomer
[1]. This is far less than reported germline rates of local
hopping but far greater than the rate in lymphomas
generated by mobilization using R26-SB11 [2]. Preliminarily,
the rate of local hopping in lymphomas generated by R26-
SB11 mobilization of transposons from a low-copy line is less
than that observed in sarcomas (Collier LS, Adams DJ, Akagi
K, Bradley A, Largaespada DA, unpublished data), indicating
that both the donor locus and transposase activity influence
local hopping rates.
There are several explanations for the decreased local
hopping rate observed in R26-SB11 lymphomas as compared
with CAGGS-SB10 sarcomas. The differences in rate could
be explained by transposon remobilization. The R26-SB11
transposase may be so active in hematopoietic cells that
transposons that do not provide a selective advantage to the
cell may have many opportunities to remobilize during
tumor development. Theoretically, the more opportunities a
single transposon has to mobilize, the greater is the chance
that it will eventually integrate in a location unlinked to the
original concatomer. Another possibility emerges from
observations recently made in our laboratory during a
germline screen using SB [21]. In this study, deletions
flanking the concatomer were frequently observed in mice
with novel transposon insertions. Deletions flanking the
concatomer were also visible using fluorescence in situ
hybridization (FISH) in somatic cells from the spleens of
transposon concatomer;R26-SB11 mice. Given this observa-
tion, a distinct possibility is that local hopping rates decrease
when R26-SB11 is used as a source of transposase because
the DNA immediately cis to the concatomer has been deleted
and therefore no insertions can be cloned from that region.
These transposition-associated deletions linked to the
concatomer can potentially complicate somatic screens
using SB or other transposable elements. For example, these
deletions could partially explain the high embryonic lethality
rates observed with high-copy T2/onc2 lines and R26-SB11.
One hypothesis is that high mobilization rates due to active
transposase or high numbers of transposons could increase
the frequency and size of these deletions. Should a large
enough deletion occur during development, it could result in
haploinsufficient lethality. These deletions could also
promote tumor development if they happen to remove one
copy of a haploinsufficient TSG. The use of array-based
comparative genome hybridization can be used to determine
whether deletions, local or genome wide, are consistently
selected for in tumors induced by SB. In addition, it will be
important to carefully characterize the genomic location of
any additional concatomers generated for somatic screens.
For example, concatomers located in a gene-poor region of
the genome might be ideal for cancer gene screens. Although
difficult with current technology, generating concatomers on
artificial chromosomes would be an ideal way to address this
issue and eliminate the concerns about local hopping and
local genomic rearrangements and deletions. Because similar
deletions have been observed with other endogenous cut-
and-paste transposable elements [36], they may also occur in
genetic screens in which such elements are mobilized from
multi-copy, chromosomally resident concatomers.
Another potential complication to the use of SB for somatic
mutagenesis is that, in the presence of continued
transposase expression, transposon remobilization may
occur. For this reason, the tumor extracted from the animal
may not possess all of the original transposon integrations
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strong selective pressure to maintain insertions in cancer
genes. Remobilization of a transposon in a cancer gene that
is providing a selective advantage could prove growth
deleterious to a cell in which it occurs, probably eliminating
that cell from the tumor clone. This would be especially true
when the tumor cell relies on the MSCV LTR in T2/onc to
over-express a proto-oncogene. However, the DNA repair
process that accompanies SB excision generates a
characteristic footprint, usually consisting of the addition of
five nucleotides, at the former insertion site [35]. It remains
possible that remobilization of a SB transposon that had
landed in a TSG would leave behind this footprint, which -
although invisible to linker-mediated polymerase chain
reaction techniques - would result in a loss-of-function
mutation. This may be true only for SB insertions into TSG
exons because the introns are much bigger targets and the
disruption of splicing caused by SB-induced footprints in
introns is likely to be a rare event. Therefore, we suspect that
most TSG mutations will remain marked by transposon
insertion in tumors. Even if TSG mutation by transposon
footprint occasionally occurs, it should be possible to
identify insertions in the TSG with analysis of enough
individual tumors. Although remobilization of SB
transposons in the germline generally is rare [32,33,37], the
remobilization rate in the soma has not been measured.
To date, the only published accounts of somatic screens
using nonviral transposable elements for cancer gene
discovery have involved the SB transposon system. This is
probably because SB was the first vertebrate active cut-and-
paste transposon characterized [23], and thus there has been
more time to develop SB for such screens. In recent years,
however, additional transposable elements that are capable
of transposing in the mouse germline and soma have been
described. Each element could have its own advantages and
disadvantages in somatic screens.
The pros and cons of other transposable
elements
Part 1: retroelements
LINE-1 elements (L1) and other retrotransposons
transpose to new locations in the genome via an RNA
intermediate. This RNA intermediate must exit the
nucleus, be translated, and be returned to the nucleus with
all the necessary enzymes to be reverse transcribed while
being inserted at a new location in the genome [38]. As a
result of this lifecycle, retroelements do not exhibit a
preference for inserting near their donor locus, which
would eliminate the local hopping complication discussed
above for SB. Both mouse and human synthetic L1
elements have been reported to retrotranspose in vitro
[39,40] and in vivo in mice transgenic for L1 expression
cassettes [41-44]. Somatic retrotransposition has been
detected in these transgenic mice [42-44]. The activities of
L1s have been improved by the identification of more
active human elements and by optimizing the translational
efficiency of murine L1 elements [40,42].
L1 elements do have potential advantages for use in somatic
mutagenesis screens. Transposed L1 elements, unlike cut-
and-paste elements, cannot remobilize. Therefore, any L1
transposition event would be fixed in all progeny of the
initial cell that suffered the integration. An additional
potential advantage for L1 as compared with cut-and-paste
elements is the potential for L1 self-expansion [45]. It has
been hypothesized that because a L1 transgene can
continually generate L1 transcripts, a theoretically infinite
expansion of L1 integrations in a somatic cell could occur.
Because DNA transposons transpose in a cut-and-paste
manner, the number of transposons in a somatic cell is
essentially limited to the number of transposons in the
chromosomal concatomer. However, there are ways in which
the number of cut-and-paste transposons in a somatic cell
could amplify, including transposition during S phase or
duplication of the chromosome harboring the transposon
concatomer [45]. However, it does appear that current
technologies involving SB provide enough transposon copies
for effective mutagenesis, because concatomers consisting of
25 copies contain sufficient numbers of transposons to
promote tumorigenesis (Collier LS, Green LE, Davies M,
Dupuy AJ, Copeland NG, Jenkins NA, Largaespada DA,
unpublished data).
In terms of insertion site preference, analysis of a small
number of insertions (n = 48) in mice transgenic for the
active human L1 element revealed only a modest preference
against inserting in RefSeq genes [42]. A survey of 170
insertions in mice transgenic for the murine L1 transgene
identified no preference for or against insertion near or in
RefSeq genes [44]. The cloning of additional insertion sites
may be necessary to address fully whether L1 has any
insertion site bias in transgenic models.
One potential obstacle to the use of L1 as a cancer gene
discovery tool, compared with cut-and-paste elements, is the
tendency of L1 to incompletely reverse transcribe the
transposon RNA as it integrates, leading to truncation. In
vivo work using a mouse transgenic that expresses a
synthetic human L1 element indicates that very few novel L1
integrations are full length, with the vast majority being
truncated at the 5’ end [42]. An analysis of 25 de novo
insertions from the synthetic murine L1 element revealed
that all were truncated at the 5’ end [44]. This could prove
deleterious to cancer screens if such truncations removed
mutagenic elements such as splice acceptors or over-
expression elements. This issue could partially be alleviated
by placing the mutagenic elements as far 3’ as possible, but
truncated elements are often quite small [42,44] and proper
design of the element will only partially ameliorate the
problem.
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Several cut-and-paste elements are known to be active in
vertebrate cells. These include Minos  [46-49],  Tol2
[25,50-52], piggyBac (PB) [25,53,54], Frog Prince [55], and
a hyperactive version of Himar1 [56-58]. Of these elements,
only Minos [49,50] and PB [54] have been tested in trans-
genic mice. Although not tested for activity in transgenic
mice, Tol2 is known to transpose in mouse embryonic stem
cells [51] and mouse liver cells when delivered using
hydrodynamics-based techniques [52]. Tol2 has several
characteristics that could make it appealing for use in
somatic mutagenesis studies. First, initial studies using Tol2
indicated that, unlike SB, the transposon can carry larger
cargo without decreased transposition efficiency [52]. This
could also be an advantage when larger mutagenesis
cassettes are needed. Second, unlike SB and PB (see below),
no evidence of over-expression inhibition has been observed
with  Tol2 [25,52]. Although it remains possible that even
higher levels of transposase could result in decreased
transposition efficiency, the current data are encouraging.
In vitro experiments have detected higher transposition
rates for PB than SB [25,59]. In vivo studies have been more
limited, but PB is known to be active in mouse one cell
embryos and in the mouse germline [54]. Unlike SB, PB
integrations studied from transposition events in vivo
indicate a strong preference for inserting in genes, because
50 out of 104 integrations occurred in validated genes (an
additional 20 integrations occurred in invalidated or
predicted genes). A recent study in vitro in human cell lines
also detected a strong preference for PB to insert into RefSeq
genes (48.8% for PB versus 39.1% for SB versus 33.2% for
random) [15,59]. If this trend holds true for somatic
integrations in vivo, then this could be an advantage for PB
in cancer genetic screens because it would increase the
probability that any mobilization event could mutate a gene.
Similar to local hopping, this preference could also
complicate CIS analysis because a random PB insertion set
would not be distributed evenly throughout the genome [14].
Initial studies indicate that, like Tol2, the PB transposon can
carry larger cargo without decreased transposition efficiency
[52,54]. However, like SB, PB is subject to over-expression
inhibition in vitro [25]. It has also been reported that PB
does not appear to local hop like many other cut-and-paste
transposons. The story is probably incomplete, however,
because this assumption was made based on only three
integrations cloned from germline transposition events from
a chromosomally resident concatomer [54]. It can be argued
that although these three events mapped to three different
chromosomes, the dataset is clearly too small to address this
question completely.
To date, published reports on Minos have found it to be only
weakly active in vivo in the mouse [48,49]. For example,
sensitive excision assays could detect Minos mobilization
from a donor concatomer in transposon/transposase doubly
transgenic mice in which transposase was expressed from a
transgene that drives expression in the thymus and spleen.
FISH was used to detect transposon sequences in these
somatic cells. In 19 of 3,114 metaphases, transposon probe
signal was detected at chromosomal sites away from the
donor concatomer [48]. However, FISH is not a very
sensitive technique for detecting single copy elements. Given
that, like SB, Minos is a member of the Tc1/Mariner family,
it is possible that the events detected by FISH could
represent chromosomal rearrangement events involving the
concatomer, similar to those we have observed with SB [21].
In the Minos study [48], the transposon donor concatomer
was located near the telomere of chromosome 14. A
chromosome 14 telomeric probe was therefore used to
determine that the donor chromosome was intact in cells
where transposon signal was found on other chromosomes.
However, it is possible that this probe did not lie sufficiently
close to the donor locus to detect genomic inversions,
translocations, or deletions involving the donor locus.
Nevertheless, somatic transposition of Minos was not
sufficiently high to be detectible by Southern analysis [48].
In the female mouse germline, a published report also
indicates that Minos is active, but only 8.2% of offspring of
transposon/transposase positive ‘seed’ females harbored
novel transposon integrations [49].
For all other mouse-active DNA transposon systems,
analysis is too preliminary to indicate the degree to which
they will have caveats such as local hopping and deletions
flanking the concatomer. However, potentially the greatest
obstacle to use of all new transposable elements - both
retroelements and cut-and-paste elements - in cancer gene
discovery is the need to achieve mobilization rates in the
soma that are sufficiently high to ensure that there is an
opportunity to insertionally mutate a cancer gene. For
example, in SB-induced lymphocytic tumors, the average
number of novel SB insertions visible by Southern blot is
about 30 [2]. In p19 Arf-/- sarcomas accelerated by SB
mobilization, the average number is about five [1]. However,
each tumor is likely to be highly polyclonal in terms of novel
integrations because the actual number of insertions cloned
per tumor was 48 in leukemias and 37 in sarcomas. To date,
although limited, all published reports on the rate of new
insertions per gamete for germline mobilizations of other
transposable elements have been significantly lower than that
achieved using SB [21,37,41,42,44,49,54]. The rate of SB
mobilization does vary from concatomer to concatomer [37],
and so the generation of additional donor concatomers for
other transposons could allow greater activity in the germline.
In addition, varying transposase (or RNA production for the
case of L1) by the use of different promoters may improve
these rates in the future. A final possibility is that no direct
comparison can or should be made between somatic,
germline, and in vitro mobilization rates, and that a
comparison between elements will only be possible once
somatic mobilization has been thoroughly tested.
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Although we can speculate on the advantages and dis-
advantages of each element, their different insertion site
preferences may mean that each element will be useful for
identifying a different set of cancer genes. For example,
although both SB and retroviruses have been used as
insertional mutagens for cancer gene discovery in lympho-
mas, comparison of cancer genes tagged by both systems
only partially overlap [2]. No matter which element is used,
such somatic screens should be designed and executed with
intense planning and forethought. Careful choice of trans-
posable element type, the mutagenic elements carried by the
transposon, the donor transposon concatomer location,
promoters for transposase or RNA expression, and even
predisposed genetic background will be instrumental in the
success of these screens in the future.
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